Concepts (200)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 12 | 2019 | 66 | 3.630 |
Why?
|
| Pancreatic Neoplasms | 8 | 2019 | 332 | 2.740 |
Why?
|
| Cone-Beam Computed Tomography | 8 | 2018 | 52 | 2.590 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 9 | 2021 | 36 | 2.130 |
Why?
|
| Radiotherapy Dosage | 10 | 2020 | 125 | 1.900 |
Why?
|
| Fiducial Markers | 4 | 2020 | 10 | 1.560 |
Why?
|
| Metal Nanoparticles | 6 | 2014 | 88 | 1.030 |
Why?
|
| Prostatic Neoplasms | 7 | 2016 | 778 | 0.990 |
Why?
|
| Gold | 4 | 2012 | 76 | 0.940 |
Why?
|
| Monte Carlo Method | 7 | 2020 | 124 | 0.920 |
Why?
|
| Rectum | 2 | 2013 | 62 | 0.860 |
Why?
|
| Motion | 3 | 2020 | 24 | 0.830 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2019 | 629 | 0.800 |
Why?
|
| Movement | 3 | 2019 | 179 | 0.760 |
Why?
|
| Phantoms, Imaging | 9 | 2020 | 189 | 0.710 |
Why?
|
| Artifacts | 1 | 2020 | 125 | 0.680 |
Why?
|
| Lung Neoplasms | 5 | 2021 | 1173 | 0.620 |
Why?
|
| Radiation Dosage | 3 | 2018 | 419 | 0.600 |
Why?
|
| Pattern Recognition, Automated | 1 | 2017 | 70 | 0.560 |
Why?
|
| Databases, Factual | 15 | 2019 | 622 | 0.530 |
Why?
|
| Radiometry | 4 | 2020 | 64 | 0.460 |
Why?
|
| Radiotherapy Setup Errors | 1 | 2013 | 1 | 0.460 |
Why?
|
| Humans | 48 | 2021 | 68618 | 0.430 |
Why?
|
| Tin | 1 | 2012 | 16 | 0.430 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2012 | 2 | 0.420 |
Why?
|
| Oropharyngeal Neoplasms | 3 | 2018 | 94 | 0.410 |
Why?
|
| Aged | 30 | 2019 | 14862 | 0.410 |
Why?
|
| Proportional Hazards Models | 13 | 2019 | 792 | 0.400 |
Why?
|
| Brachytherapy | 4 | 2018 | 79 | 0.390 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2015 | 689 | 0.370 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2019 | 536 | 0.350 |
Why?
|
| Propensity Score | 10 | 2018 | 117 | 0.350 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2019 | 125 | 0.340 |
Why?
|
| Brain Neoplasms | 3 | 2018 | 371 | 0.330 |
Why?
|
| Survival Analysis | 8 | 2018 | 714 | 0.330 |
Why?
|
| Melanoma | 3 | 2017 | 335 | 0.330 |
Why?
|
| Middle Aged | 26 | 2019 | 21147 | 0.300 |
Why?
|
| Stomach Neoplasms | 2 | 2017 | 64 | 0.280 |
Why?
|
| Head and Neck Neoplasms | 3 | 2017 | 561 | 0.280 |
Why?
|
| Male | 32 | 2019 | 37321 | 0.280 |
Why?
|
| Laryngeal Neoplasms | 2 | 2017 | 47 | 0.280 |
Why?
|
| Aged, 80 and over | 15 | 2019 | 4848 | 0.280 |
Why?
|
| Neoplasm Staging | 9 | 2018 | 800 | 0.270 |
Why?
|
| Mediastinal Neoplasms | 2 | 2016 | 27 | 0.270 |
Why?
|
| Insurance, Health | 2 | 2018 | 201 | 0.260 |
Why?
|
| Respiration | 2 | 2017 | 91 | 0.260 |
Why?
|
| Four-Dimensional Computed Tomography | 3 | 2021 | 6 | 0.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 468 | 0.240 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2018 | 300 | 0.240 |
Why?
|
| Survival Rate | 8 | 2019 | 1056 | 0.240 |
Why?
|
| Adenocarcinoma | 2 | 2017 | 475 | 0.240 |
Why?
|
| Multivariate Analysis | 8 | 2019 | 1046 | 0.230 |
Why?
|
| Computer Simulation | 2 | 2020 | 706 | 0.230 |
Why?
|
| United States | 15 | 2019 | 7367 | 0.220 |
Why?
|
| Chemoradiotherapy | 6 | 2018 | 54 | 0.210 |
Why?
|
| Insurance Coverage | 3 | 2018 | 99 | 0.210 |
Why?
|
| Color | 2 | 2012 | 50 | 0.200 |
Why?
|
| Female | 26 | 2019 | 38074 | 0.200 |
Why?
|
| Radiation Pneumonitis | 1 | 2021 | 4 | 0.200 |
Why?
|
| Radiotherapy | 3 | 2016 | 86 | 0.200 |
Why?
|
| Margins of Excision | 2 | 2018 | 15 | 0.200 |
Why?
|
| Cranial Irradiation | 2 | 2018 | 8 | 0.190 |
Why?
|
| Retrospective Studies | 9 | 2018 | 7277 | 0.190 |
Why?
|
| Adult | 19 | 2019 | 21403 | 0.190 |
Why?
|
| Lymphatic Metastasis | 2 | 2019 | 274 | 0.190 |
Why?
|
| Cisplatin | 2 | 2018 | 192 | 0.180 |
Why?
|
| Acoustics | 1 | 2020 | 20 | 0.180 |
Why?
|
| Radiotherapy, Conformal | 2 | 2017 | 24 | 0.180 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2017 | 33 | 0.180 |
Why?
|
| Alphapapillomavirus | 2 | 2018 | 17 | 0.170 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2019 | 12 | 0.170 |
Why?
|
| Cancer Care Facilities | 1 | 2019 | 32 | 0.160 |
Why?
|
| Cetuximab | 1 | 2018 | 19 | 0.160 |
Why?
|
| Carboplatin | 1 | 2018 | 59 | 0.160 |
Why?
|
| Immunotherapy | 2 | 2017 | 215 | 0.160 |
Why?
|
| Nomograms | 1 | 2018 | 19 | 0.160 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2018 | 17 | 0.160 |
Why?
|
| Follow-Up Studies | 7 | 2018 | 3259 | 0.150 |
Why?
|
| Tumor Burden | 1 | 2018 | 132 | 0.150 |
Why?
|
| Carcinosarcoma | 1 | 2018 | 12 | 0.150 |
Why?
|
| Normal Distribution | 1 | 2017 | 46 | 0.150 |
Why?
|
| Prognosis | 6 | 2018 | 2093 | 0.150 |
Why?
|
| Uterine Neoplasms | 1 | 2018 | 99 | 0.150 |
Why?
|
| Glottis | 1 | 2017 | 17 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2019 | 129 | 0.150 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2017 | 2 | 0.150 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2017 | 10 | 0.150 |
Why?
|
| Young Adult | 9 | 2019 | 5717 | 0.150 |
Why?
|
| Perioperative Care | 1 | 2018 | 100 | 0.150 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2017 | 23 | 0.140 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2017 | 12 | 0.140 |
Why?
|
| Thymoma | 1 | 2017 | 14 | 0.140 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2017 | 14 | 0.140 |
Why?
|
| Thymus Neoplasms | 1 | 2017 | 17 | 0.140 |
Why?
|
| Nose Neoplasms | 1 | 2017 | 25 | 0.140 |
Why?
|
| Combined Modality Therapy | 5 | 2016 | 951 | 0.140 |
Why?
|
| Induction Chemotherapy | 1 | 2017 | 39 | 0.140 |
Why?
|
| Mouth Neoplasms | 1 | 2019 | 206 | 0.140 |
Why?
|
| SEER Program | 4 | 2018 | 153 | 0.140 |
Why?
|
| Anal Canal | 1 | 2016 | 28 | 0.140 |
Why?
|
| Cholangiocarcinoma | 1 | 2016 | 20 | 0.140 |
Why?
|
| Dacarbazine | 1 | 2016 | 32 | 0.140 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2016 | 40 | 0.140 |
Why?
|
| Bile Duct Neoplasms | 1 | 2016 | 39 | 0.140 |
Why?
|
| Pancreas | 1 | 2017 | 225 | 0.140 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2016 | 57 | 0.130 |
Why?
|
| Database Management Systems | 1 | 2016 | 25 | 0.130 |
Why?
|
| Postoperative Care | 1 | 2017 | 163 | 0.130 |
Why?
|
| Observer Variation | 1 | 2017 | 330 | 0.130 |
Why?
|
| Anus Neoplasms | 1 | 2016 | 37 | 0.130 |
Why?
|
| Catheter Ablation | 1 | 2018 | 229 | 0.130 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2018 | 163 | 0.130 |
Why?
|
| Lymphoma, B-Cell | 1 | 2016 | 40 | 0.130 |
Why?
|
| Androgen Antagonists | 4 | 2016 | 45 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 2324 | 0.130 |
Why?
|
| Carcinoma | 1 | 2017 | 215 | 0.130 |
Why?
|
| Fourier Analysis | 1 | 2015 | 31 | 0.130 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2015 | 47 | 0.130 |
Why?
|
| Treatment Outcome | 8 | 2018 | 7029 | 0.120 |
Why?
|
| Medically Uninsured | 1 | 2015 | 99 | 0.120 |
Why?
|
| Gold Compounds | 2 | 2014 | 2 | 0.120 |
Why?
|
| Algorithms | 3 | 2020 | 1196 | 0.120 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 334 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 378 | 0.120 |
Why?
|
| Spectrometry, Fluorescence | 2 | 2011 | 112 | 0.120 |
Why?
|
| Quality Control | 1 | 2013 | 81 | 0.110 |
Why?
|
| Glioblastoma | 1 | 2016 | 219 | 0.110 |
Why?
|
| Medicaid | 1 | 2015 | 302 | 0.110 |
Why?
|
| Lead | 1 | 2012 | 45 | 0.110 |
Why?
|
| Adolescent | 7 | 2019 | 8912 | 0.110 |
Why?
|
| Disease-Free Survival | 3 | 2017 | 349 | 0.100 |
Why?
|
| Haemophilus | 1 | 2011 | 1 | 0.100 |
Why?
|
| Feasibility Studies | 2 | 2011 | 652 | 0.100 |
Why?
|
| Haemophilus Infections | 1 | 2011 | 15 | 0.100 |
Why?
|
| Genome, Bacterial | 1 | 2011 | 20 | 0.100 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 375 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2017 | 2358 | 0.090 |
Why?
|
| Neoplasms | 3 | 2018 | 1667 | 0.090 |
Why?
|
| Analysis of Variance | 3 | 2017 | 1040 | 0.090 |
Why?
|
| Gamma Rays | 1 | 2009 | 64 | 0.080 |
Why?
|
| Gastrectomy | 2 | 2017 | 24 | 0.070 |
Why?
|
| Lymph Nodes | 2 | 2019 | 258 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 2 | 2017 | 104 | 0.070 |
Why?
|
| Time Factors | 3 | 2020 | 4655 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 369 | 0.070 |
Why?
|
| Neoplasm Grading | 2 | 2016 | 111 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 2 | 2016 | 138 | 0.060 |
Why?
|
| Lung | 2 | 2021 | 849 | 0.060 |
Why?
|
| Age Factors | 2 | 2019 | 1864 | 0.050 |
Why?
|
| Photons | 2 | 2014 | 32 | 0.050 |
Why?
|
| Registries | 2 | 2016 | 733 | 0.050 |
Why?
|
| X-Rays | 2 | 2014 | 56 | 0.050 |
Why?
|
| Fluorescence | 2 | 2014 | 104 | 0.050 |
Why?
|
| Pulmonary Ventilation | 1 | 2021 | 28 | 0.050 |
Why?
|
| Postoperative Period | 1 | 2019 | 238 | 0.040 |
Why?
|
| Income | 1 | 2019 | 167 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 50 | 0.040 |
Why?
|
| Hysterectomy | 1 | 2018 | 64 | 0.040 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2017 | 30 | 0.040 |
Why?
|
| Respiratory Mechanics | 1 | 2017 | 33 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2017 | 35 | 0.040 |
Why?
|
| Age Distribution | 1 | 2017 | 320 | 0.040 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2017 | 62 | 0.030 |
Why?
|
| Laryngectomy | 1 | 2016 | 30 | 0.030 |
Why?
|
| Datasets as Topic | 1 | 2016 | 53 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 306 | 0.030 |
Why?
|
| Skin Ulcer | 1 | 2015 | 19 | 0.030 |
Why?
|
| Rituximab | 1 | 2016 | 61 | 0.030 |
Why?
|
| Risk Factors | 2 | 2016 | 5731 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2016 | 99 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 1266 | 0.030 |
Why?
|
| Pelvis | 1 | 2015 | 38 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2017 | 275 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1426 | 0.030 |
Why?
|
| Scattering, Radiation | 1 | 2014 | 30 | 0.030 |
Why?
|
| Prostate | 1 | 2015 | 116 | 0.030 |
Why?
|
| Spectrum Analysis | 1 | 2014 | 81 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2077 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2018 | 1553 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 1420 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 931 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2014 | 384 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2017 | 2455 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 2007 | 0.020 |
Why?
|
| Electrons | 1 | 2010 | 25 | 0.020 |
Why?
|
| Infant | 1 | 2017 | 2891 | 0.020 |
Why?
|
| Tellurium | 1 | 2010 | 4 | 0.020 |
Why?
|
| Cadmium Compounds | 1 | 2010 | 6 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2017 | 3187 | 0.020 |
Why?
|
| Polymethyl Methacrylate | 1 | 2010 | 31 | 0.020 |
Why?
|
| Base Sequence | 1 | 2011 | 1015 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 2010 | 136 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 1070 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 3705 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 2279 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 1447 | 0.020 |
Why?
|
| Water | 1 | 2010 | 230 | 0.020 |
Why?
|
| Child | 1 | 2017 | 6405 | 0.020 |
Why?
|
| Models, Biological | 1 | 2010 | 981 | 0.020 |
Why?
|
| Animals | 1 | 2010 | 20881 | 0.010 |
Why?
|